Lead. The idea that the bacteria living in your gut can influence how well you sleep has moved from intriguing hypothesis to clinically testable therapy. A new randomized, double-blind, placebo-controlled trial published in the Journal of Internal Medicine provides the most rigorous evidence to date that transferring gut microbiota from healthy donors into people with chronic insomnia can produce objectively measured improvements in sleep efficiency, with effects lasting up to six months.
The study, led by Teng Gao, Xiaoxing Liu, and a large team from multiple Chinese medical institutions along with Michael V. Vitiello of the University of Washington, tested whether fecal microbiota transplantation (FMT) could improve sleep in adults with chronic insomnia disorder. Eighty participants were randomly assigned to receive either donor microbiota capsules or placebo capsules, and every participant underwent overnight polysomnography, the gold standard of objective sleep measurement, to determine whether the treatment actually changed how they slept.
What they found. The primary outcome was sleep efficiency, the percentage of time in bed actually spent asleep, measured by polysomnography one month after treatment. The FMT group showed a dramatic improvement. The adjusted between-group difference was 13.9 percentage points, a result that was statistically significant (p = 0.003). In practical terms, this means that someone who spent 70 percent of their time in bed asleep, a typical figure for moderate insomnia, would gain roughly an extra hour of sleep per seven-hour night after FMT treatment.
The improvement was not just a statistical artifact. FMT also significantly reduced wake after sleep onset, the amount of time spent awake during the night after initially falling asleep, which is one of the most distressing symptoms for people with insomnia. And the benefits did not fade quickly. Scores on the Insomnia Severity Index and the Pittsburgh Sleep Quality Index, two widely used clinical questionnaires, showed sustained improvement from the two-month follow-up through the six-month mark. The treatment was well tolerated, with no serious adverse events reported.
Interestingly, the researchers also tested whether adding synbiotics, a combination of probiotics and prebiotics, could enhance the effect of FMT. Within each group, a subgroup received either synbiotic supplementation or a matching placebo. The synbiotic assignment made no meaningful difference, suggesting that the key therapeutic effect came from the initial microbiota transplant itself, not from ongoing microbial support.
On the biological side, FMT increased the richness and diversity of the gut microbiota in recipients, a shift toward a healthier microbial ecosystem. Perhaps most intriguingly, baseline microbiota composition differed between participants who responded to treatment and those who did not. This raises the possibility that a simple stool sample could one day help predict which patients are most likely to benefit from FMT, moving the field toward personalized microbiota-based sleep medicine.
Why it matters. Chronic insomnia is extraordinarily common. Recent global estimates published in Sleep Medicine Reviews suggest that roughly 850 million adults worldwide, or about 16 percent of the adult population, meet criteria for clinically relevant insomnia. Nearly half of those cases are classified as severe. Existing treatments have significant limitations. Cognitive behavioral therapy for insomnia, the recommended first-line approach, is highly effective but faces major access barriers, including a shortage of trained therapists and high cost. Pharmacological options, including benzodiazepine receptor agonists and dual orexin receptor antagonists, carry risks of tolerance, dependence, and side effects that limit their long-term use. The need for mechanistically novel treatments is real.
The gut-brain axis offers a fundamentally different approach. Over the past decade, a growing body of research has shown that the gut microbiota communicates with the brain through multiple pathways, including the vagus nerve, the production of short-chain fatty acids, the modulation of tryptophan metabolism, and the regulation of immune signaling and neuroinflammation. Specific bacterial species, particularly those in the genera Lactobacillus and Bifidobacterium, produce neurotransmitters such as gamma-aminobutyric acid (GABA) and serotonin, both of which are deeply involved in sleep regulation. Studies in mice have shown that transplanting microbiota from insomnia patients into germ-free animals can induce insomnia-like behaviors, while administering the microbial metabolite butyrate can rescue those sleep disturbances.
What has been missing until now is a properly controlled human trial that measures sleep objectively rather than relying solely on self-reported questionnaires. Previous studies of FMT for insomnia were open-label, real-world observations that, while suggestive, could not rule out placebo effects. Insomnia is notoriously susceptible to placebo responses, particularly when subjective measures are used. The new trial addresses this gap with a double-blind design, a placebo control, and polysomnography as the primary endpoint.
The fact that synbiotic supplementation did not add benefit also simplifies the clinical picture. It suggests that restoring a healthy baseline microbiota through a single transplantation course, rather than continuous probiotic maintenance, may be sufficient to produce durable sleep improvements. This is consistent with the observation that FMT increased microbial richness and diversity, essentially rebooting the ecosystem rather than merely supplementing it.
Limits. The trial enrolled 80 participants, a moderate sample size. While the effect size on sleep efficiency was large, the confidence interval was relatively wide (7.29 to 20.41 percentage points), reflecting some variability in individual response. The study was conducted at multiple Chinese centers, and the donor microbiota was sourced from healthy Chinese donors, meaning the results may not generalize to other populations with different dietary habits, genetic backgrounds, and baseline microbiota compositions. The six-month follow-up is encouraging but does not answer whether the benefits persist beyond that window or whether repeat FMT sessions might be needed. The finding that baseline microbiota differed between responders and non-responders is provocative but based on a relatively small number of participants in each subgroup; it requires replication in a larger cohort specifically designed to test predictive biomarkers. Finally, the mechanism by which FMT improves sleep efficiency is not fully established by this trial. While the microbiota changes were measured, the study did not directly track the neurotransmitter or metabolite pathways that may mediate the sleep effects.
Bottom line. Fecal microbiota transplantation improved objectively measured sleep efficiency by nearly 14 percentage points in adults with chronic insomnia, with benefits sustained for six months. The trial represents the strongest evidence yet that manipulating the gut microbiota can produce clinically meaningful sleep improvements and opens a new avenue for insomnia treatment that operates through a mechanism entirely distinct from existing pharmacological and behavioral therapies.
Source. Gao T, Liu X, Mi W, et al. Fecal microbiota transplantation-based treatment protocol for chronic insomnia disorder: A randomized, double-blind, placebo-controlled trial. Journal of Internal Medicine. 2026 Jul 22. DOI: 10.1111/joim.70137. PMID: 42482568. Multi-institutional: Peking University Sixth Hospital, Peking University, University of Washington, and others. Funding: National Science and Technology Major Project and National Natural Science Foundation of China.